aibioBriaCell plans 1-for-10 share consolidation to meet Nasdaq listing rules
BriaCell's board approved a one-for-ten share consolidation to keep its Nasdaq listing, expected to take effect August 25, 2025, subject to approval from Nasdaq and the Toronto Stock Exchange.
Key facts
- Companies
- BriaCell Therapeutics Corp (TSX: BCT), BriaCell Therapeutics Corp. (NASDAQ: BCTX)
- News type
- Listings
- Primary source
- BriaCell Therapeutics Corp 8-K (2025-08-26)
BriaCell Therapeutics Corp. (Nasdaq: BCTX; TSX: BCT) announced on August 21, 2025 that its board of directors approved a consolidation of its common shares on the basis of one post-consolidation share for every ten pre-consolidation shares. The company filed the announcement as Exhibit 99.1 to a Form 8-K filed on August 26, 2025. The release is datelined Philadelphia and Vancouver.
Why the company is consolidating
The release says the consolidation is being carried out to ensure that the company continues to comply with the listing requirements of The Nasdaq Capital Market. It does not name the specific requirement at issue, the share price that prompted the step or the period it measures. It describes the reason only in those general terms.
Timing and conditions
The consolidation is subject to approval by the Toronto Stock Exchange and by Nasdaq. The company expected it to take effect on August 25, 2025, with post-consolidation shares trading at market open on or about that date, subject to final confirmation from both exchanges. The 8-K attaches the release, but it does not confirm that the consolidation took effect or report either exchange's final confirmation.
After the consolidation, the release says the shares are expected to trade on the TSX under BCT and on Nasdaq under BCTX. It lists BCTXW and BCTXZ among the company's Nasdaq securities, and it does not say how those securities will change.
The release says the exercise or conversion price and the number of shares issuable under outstanding convertible securities will be adjusted in proportion. It does not give the resulting figures.
Fractions, holders and the transfer agent
No fractional shares will be issued. Fractions of less than one half share will be cancelled, and fractions of at least one half share will be rounded up to one whole share. The company says it will not round up at the beneficial level and will instead round up at the participant level.
Computershare Investor Services Inc. is the transfer agent. It will send a letter of transmittal to registered holders of record as of the effective date. Until a certificate or direct registration statement is surrendered, it will represent the whole post-consolidation shares the holder is entitled to receive. Beneficial holders need take no action, but those with questions should contact their intermediary.
The company behind the split
The annual report filed in October 2024 describes BriaCell as a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care. Its lead program is Bria-IMT, a targeted immunotherapy given with retifanlimab, an immune checkpoint inhibitor, in a pivotal Phase 3 study in metastatic breast cancer. The report says Bria-IMT has Fast Track designation from the FDA. It also says that positive completion of the pivotal study, followed by FDA review, could lead to full approval of the combination.
The report cites a median overall survival of 13.4 months in its metastatic breast cancer patients, against 6.7 to 9.8 months for similar patients reported in the literature. Those figures compare different studies, so they cannot show that the difference came from the drug. The report defines a pivotal study as a Phase 3 study intended to show and confirm the safety and efficacy of a treatment.
What the release leaves out
The release is about the mechanics of a share split, not the company's finances. It does not give a cash balance, a loss figure or an update on the pivotal study. It refers readers to the risks in the company's management's discussion, its annual information form and its SEC filings, but it summarizes none of them.
A consolidation changes the number of shares and the price per share together. It does not change the company's cash or the cost of the Phase 3 study. The release does not say whether the company expects to meet the requirement it cites once the split takes effect.